The study was supported by Alba Therapeutics. Dr. Murray reported serving as a consultant to or on the advisory boards of nearly a dozen pharmaceutical companies, Alba not among them. Dr. Lebwohl reported having no financial conflicts.
Conference Coverage
Larazotide eased symptoms in phase II celiac trial
More IBD & Intestinal Disorders News
- Celiac disease: Update on diagnosis and monitoring
- Male IBD medication use doesn’t hamper reproduction, analysis suggests
- Mirikizumab performs well in UC new data show
- Surveillance colonoscopy: When and how to stop
- No link between PPIs and dementia in new study
- IBD study characterizes biologic adherence, confirms nonadherence risk factors
- Medtronic to discontinue SmartPill capsule
- AGA offers guidance on gastric peroral endoscopic myotomy for gastroparesis
Question 1 of 5